Month: March 2023

Regulated Information Leuven, BELGIUM, Boston, MA, US – March 31, 2023 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions....

2022 was the most successful year in history for Admirals Group AS  2022 was the most successful of Admirals’ 22 years of operation. The company achieved records in net trading revenue, net profit and active customers, acquired licenses in South Africa and Canada, and strongly continued to strategically implement the 2030 vision to enable financial freedom for 10 million people. Admirals Group AS net trading income 69.0 million euros (2021: 35.7 million euros)  Admirals Group AS net profit 24.3 million euros (2021: 0.1 million euros)  “As a global FinTech community, Admirals has always stood for the values that connect people and cultures all around the world. Financial freedom is one of the next great objectives of humankind and we believe that it should be within reach for everybody and everywhere. Our aim is to be a trustful...

Haverford, PA, March 31, 2023 (GLOBE NEWSWIRE) — Investview, Inc. (OTCQB: INVU), a diversified financial technology company that through its subsidiaries and global distribution network provides financial technology, education tools, content, research, and management of digital asset technologies with a focus on Bitcoin mining and the new generation of digital assets, is pleased to announce its financial results for the twelve months ended December 31, 2022. Summary Consolidated Financial Highlights: Results of Operations and Net Cash Provided by Operating Activities-Twelve Months Ended December 31, 2022 vs Nine Months Ended December 31, 20211Gross Revenue (a Non-GAAP measure) decreased 23.4% to $66.6 million for the twelve months ended December 31, 2022, as compared to $86.9 million for the nine months ended December 31, 2021. Net...

2022 was the most successful for the company 2022 was the most successful of Admirals’ 22 years of operation. The company achieved records in net trading revenue, net profit and active customers, acquired licenses in South Africa and Canada, and strongly continued to strategically implement the 2030 vision to enable financial freedom for 10 million people. Admiral Markets AS net trading income 44,3 million euros (2021: 20,5 million euros)  Admiral Markets AS net profit 24,8 million euros (2021: 0.9 million euros)  “As a global FinTech community, Admirals has always stood for the values that connect people and cultures all around the world. Financial freedom is one of the next great objectives of humankind and we believe that it should be within reach for everybody and everywhere. Our aim is to be a trustful financial partner...

Vilnius, Lithuania, 31 March 2023 The revenue of Vilniaus Baldai AB and its subsidiaries (“the Group”) stood at 48 869 thousand EUR during September of 2022 – February of 2023, while during the same period of FY2022 revenue was 49 781 thousand EUR. Net loss of the Group during September of 2022 – February of 2023 was 2 048 thousand EUR, while   EBITDA was 1 025 thousand EUR. Net profit of the Group during September of 2021– February of 2022 was 6 808 thousand EUR, while EBITDA was 9 864 thousand EUR. The revenue of the Group stood at 20 434 thousand EUR during December of 2022 – February of 2023, while during the same period of FY2022 the revenue of the Group was 22 934 thousand EUR. Net loss of the Group during December of 2022 – February of 2023 was 1 469 thousand EUR, while EBITDA was 33 thousand EUR. Net profit of the Group during...

March 31, 2023 SBM Offshore is pleased to announce it has signed the project financing of FPSO Almirante Tamandaré for a total of US$1.63 billion. The project financing is provided by a consortium of 13 international banks with insurance cover from 4 international Export Credit Agencies (ECA). The financing is composed of five separate facilities with a ca. 6.3% weighted average cost of debt and a 14-year post-completion maturity for both the ECA covered facilities and the uncovered facility. The FPSO’s design incorporates SBM Offshore’s industry leading Fast4Ward® new build, multi-purpose hull. It will be the largest oil producing unit in Brazil with a processing capacity of 225,000 barrels of oil and 12 million m3 of gas per day. The FPSO will have an estimated greenhouse gas (GHG) emission intensity below 10 kgCO2e/boe1 and will benefit...

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the full year ended December 31, 2022, and provide a general business update. The financial results will be issued in a press release on Friday, March 31, 2023. Webcast Information:Date: Monday, April 3, 2023Time: 4:30 p.m. Eastern time (1:30 a.m. Pacific time)Webcast Link: https://lifescievents.com/event/belite-bio-event/Webcast Link InstructionsYou can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website...

VANCOUVER, British Columbia, March 31, 2023 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced its Quebrada Blanca Phase 2 Project (“QB2”) has produced its first bulk copper concentrate, as the project advances commissioning and ramps up to full production through 2023. “First copper concentrate production at QB2 is an important milestone as we advance our commissioning and ramp up plan towards full production this year,” said Jonathan Price, CEO. “This achievement is made possible by the dedicated and skilled teams who have worked diligently to progress this transformative operation, which is the cornerstone of our copper growth strategy.” At full production, QB2 will double Teck’s copper production on a consolidated basis. As one of the world’s largest undeveloped copper resources,...

BBS-Bioactive Bone Substitutes Plc, Company announcement, Inside information, 31 March 2023 at 7.45 p.m. (EEST) BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC BBS-Bioactive Bone Substitutes Plc (“BBS, “Company”) has today renewed the company’s capital facility agreement announced on September 30, 2021 with Riverfort Global Opportunities PCC (“RiverFort”) and the maturity dates of repayment installments have been extended by one year. For the first installment the maturity date is 31 March 2024 (previously 31 March 2023) and for the second it is 22 August 2024 (previously 22 August 2024). Key commercial terms and conditions remain unchanged. The reference price on the outstanding amount is recalculated according to the agreement terms to be now EUR 1.008 per share. Consequently,...